Market Place
Sourcing Support
Schrödinger Appoints Mannix Aklian as Chief Commercial Officer
29 May 2025 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq LR 5635(c)(4)
29 May 2025 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq LR 5635(c)(4)
23 May 2025 //
BUSINESSWIRE
Schrodinger to Present at Jefferies Global Healthcare Conference
22 May 2025 //
BUSINESSWIRE
Schrödinger lays Off 60 Workers to Reduce Cash Burn
20 May 2025 //
FIERCE BIOTECH
Schrödinger to Present Ph 1 Data on MALT1 Inhibitor at EHA
14 May 2025 //
BUSINESSWIRE
Schrodinger Reports Strong First Quarter 2025 Financial Results
07 May 2025 //
BUSINESSWIRE
Schrödinger to Present at BofA Securities 2025 Healthcare Conf.
05 May 2025 //
BUSINESSWIRE
Schredinger Presents New Preclinical Data at AACR Annual Meeting
28 Apr 2025 //
BUSINESSWIRE
Schrödinger to Announce Q1 2025 Financial Results on May 7
23 Apr 2025 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Rule 5635(c)(4
18 Apr 2025 //
BUSINESSWIRE
Schrödinger`s response to FDA plan to phase out animal testing
14 Apr 2025 //
BUSINESSWIRE
Schrdinger to Present Preclinical Data at AACR Annual Meeting
25 Mar 2025 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
18 Mar 2025 //
BUSINESSWIRE
Schrödinger Appoints Bridget van Kralingen to Board of Directors
10 Mar 2025 //
BUSINESSWIRE
Schrödinger Reports Strong Q4 and Full-Year 2024 Financial Results
26 Feb 2025 //
BUSINESSWIRE
Schrödinger to Participate in Upcoming Investor Conferences
24 Feb 2025 //
BUSINESSWIRE
Schrodinger To Report Q4 & Full-Year 2024 Results On Feb 26
12 Feb 2025 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq LR 5635(c)(4)
22 Jan 2025 //
BUSINESSWIRE
Schrödinger Outlines Progress and Strategic Focus for 2025 Goals
13 Jan 2025 //
BUSINESSWIRE
Schrödinger to Present at Piper Sandler Healthcare Conference
20 Nov 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
19 Nov 2024 //
BUSINESSWIRE
Novartis pays Schrödinger $150M to form drug discovery pact
13 Nov 2024 //
PR NEWSWIRE
Schrödinger Reports Q3 2024 Financial Results
12 Nov 2024 //
BUSINESSWIRE
Schrödinger to Present at Jefferies London Healthcare Conference
04 Nov 2024 //
BUSINESSWIRE
Schrödinger Presents SGR-3515 Data at EORTC-NCI-AACR Symposium
23 Oct 2024 //
BUSINESSWIRE
Schrödinger to Present Preclinical Data at 2024 EORTC Symposium
09 Oct 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants Under Nasdaq Rule
18 Sep 2024 //
BUSINESSWIRE
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
14 Aug 2024 //
BUSINESSWIRE
Schrödinger Reports Strong Second Quarter 2024 Financial Results
31 Jul 2024 //
BUSINESSWIRE
Schrödinger Expands Computational Tools For Predictive Toxicology
26 Jul 2024 //
BUSINESSWIRE
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
17 Jul 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16 Jul 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
14 Jun 2024 //
BUSINESSWIRE
Schrödinger to Present at Jefferies Global Healthcare Conference
22 May 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
17 May 2024 //
BUSINESSWIRE
Schrödinger Reports First Quarter 2024 Financial Results
01 May 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
18 Apr 2024 //
BUSINESSWIRE
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
10 Apr 2024 //
BUSINESSWIRE
Schrödinger Highlights Discovery of SGR-1505 at ACS National Meeting
20 Mar 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
19 Mar 2024 //
BUSINESSWIRE
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Schrödinger to Participate in Upcoming Investor Conferences
20 Feb 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16 Feb 2024 //
BUSINESSWIRE
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results
14 Feb 2024 //
BUSINESSWIRE
Schrödinger takes a step forward with AlphaFold in drug R&D
01 Feb 2024 //
ENDPTS
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
19 Jan 2024 //
BUSINESSWIRE
Schrödinger Provides Update on Progress Across the Business Goals
08 Jan 2024 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
19 Dec 2023 //
BUSINESSWIRE
Schrödinger Highlights Progress of Clinical Programs
14 Dec 2023 //
BUSINESSWIRE
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921
10 Dec 2023 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
17 Nov 2023 //
BUSINESSWIRE
Schrödinger to Participate in Upcoming Investor Conferences
06 Nov 2023 //
BUSINESSWIRE
Schrödinger to Present New Data for SGR-1505 and SGR-2921
02 Nov 2023 //
BUSINESSWIRE
Schrödinger Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
BUSINESSWIRE
Schrödinger to Host Pipeline Day on December 14, 2023
30 Oct 2023 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
23 Oct 2023 //
BUSINESSWIRE
Schrödinger to Announce Third Quarter 2023 Financial Results on November 1
18 Oct 2023 //
BUSINESSWIRE
Schrödinger and Two City University of New York Colleges Awarded $1M NSF Grant
28 Sep 2023 //
BUSINESSWIRE
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
18 Sep 2023 //
BUSINESSWIRE
